Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Meptazinol→

Meptazinol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
54340-58-8
Molecular formula
C15H23NO
Molecular weight
233.35 g/mol
Drug class
Centrally acting opioid analgesicmixed opioid agonist–antagonist
Mechanism of action
Produces analgesia through mixed agonist–antagonist activity at opioid receptors, with a predominant component of mu-opioid receptor activity. It also has central cholinergic effects that may contribute to its analgesic profile.
Indications / reported uses
  • Relief of moderate-to-severe acute pain, including postoperative and obstetric pain, with authorised oral or injectable products.

Sources: https://patient-info.co.uk/meptid-tablets-200-mg-92341/summary-of-medicine-characteristics · https://www.ncbi.nlm.nih.gov/mesh/68008621 · https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9083 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Meptazinol Environmental Risk Assessment (ERA) (the Meptazinol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.